Now Available, FOLR1 IHC Testing from Foundation Medicine.
Foundation Medicine is now offering FOLR1 IHC testing to help you identify patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, who are folate receptor alpha positive and may be eligible for mirvetuximab soravtansine-gynx.
In addition to FoundationOne®CDx, which reports HRD status, FOLR1 testing from Foundation Medicine could help you identify more treatments for patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
If you are interested in receiving direct outreach from your Foundation Medicine representative regarding FOLR1 IHC testing, please share your contact information below.
The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is for prescription use only and is a qualitative IHC assay intended for use in the assessment of folate receptor alpha (FOLR1) in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, or primary peritoneal cancer tissue specimens. This assay is FDA-approved and is indicated as an aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who may be eligible for treatment with Elahere (mirvetuximab soravtansine-gynx). Test results should be interpreted in conjunction with relevant clinical information. For the complete label please visit https://www.accessdata.fda.gov/cdrh_docs/pdf22/P220006C.pdf
FoundationOne®CDx is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors and is for prescription use only. The test analyzes 324 genes as well as genomic signatures including microsatellite instability (MSI) and tumor mutational
burden (TMB) and is a companion diagnostic to identify patients who may benefit from treatment with specific therapies in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.F1CDxLabel.com